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RNA regulon/operona protein PML and its associated nuclear bodies are hot topics of investigation.
This interest arises for multiple reasons including the tight link between the integrity of PML nuclear bodies
and several disease states and the impact of the PML protein and PML nuclear bodies on proliferation,
apoptosis and viral infection. Unfortunately, an understanding of the molecular underpinnings of PML
nuclear body function remains elusive. Here, a general overview of the PML ﬁeld is provided and is extended
to discuss whether some of the basic tenets of “PML-ology” are still valid. For instance, recent ﬁndings
suggest that some components of PML nuclear bodies form bodies in the absence of the PML protein. Also, a
new model for PML nuclear body function is proposed which provides a unifying framework for its effects on
diverse biochemical pathways such as Akt signaling and the p53-Mdm2 axis. In this model, the PML protein
acts as an inhibitor of gene expression post-transcriptionally via inhibiting a network node in the eIF4E RNA
regulon. An example is given for how the PML RNA regulon model provided the basis for the development of
a new anti-cancer strategy being tested in the clinic.
© 2008 Elsevier B.V. All rights reserved.1. Brief overview of the PML protein and PML nuclear bodiesIn the last almost 20 years, many groups have focused their
attention on the structure and function of the promyelocytic leukemia
protein PML and its associated nuclear structures referred to as PML
nuclear bodies (PML NBs), PML oncogenic domains (PODs), Kremer
bodies or ND10s (nuclear dot 10). The PML protein was the ﬁrst
identiﬁed component of these nuclear structures and remains their
deﬁning feature. General interest in the PML ﬁeld has arisen due to the
disruption/alteration of PML nuclear bodies in several pathogenic
conditions including acute promyelocytic leukemia (APL) [1–3] and
polyglutamine repeat neurodegenerative diseases [4–6], as well as a
wide variety of viral infections including HIV and lymphocytic
choriomeningitis virus (LCMV) [7–10]. The PML protein is expressed
in all mammalian tissue types reported thus far [11]. Importantly, the
PML protein appears to be conserved in mammals but seems to be
absent from lower eukaryotes and plants [12].
What has captured the attention of many investigators is the
potent growth suppressive and apoptotic roles of the PML protein, and
the correlation of these activities to the structural integrity of the
nuclear bodies. When overexpressed, the PML protein inhibits cell
cycle progression leading to G1/S arrest, suppresses some forms ofcer, Université de Montréal,
l rights reserved.oncogenic transformation, promotes apoptosis as well as Ras induced
senescence [12–15]. Recent reports suggest that the PML protein may
even play roles in the suppression of angiogenesis thereby impacting
on metastases [16]. How does the PML protein achieve these physio-
logical affects? At the molecular level, PML nuclear bodies have been
suggested to play roles in mRNA export [17–21], DNA repair [2,22–25],
DNA replication [22,26,27], transcription [28–30], and PML nuclear
bodies may act as sites for post-translational modiﬁcations (e.g. SUMO
modiﬁcation, acetylation and phosphorylation) [31–34], to name a
few. There is no framework postulated that could provide a molecular
basis for these diverse biochemical activities and thereby unite these
seemingly unrelated functionalities. This may be difﬁcult as it seems
likely that all PML nuclear bodies will not be functionally equivalent
in all contexts [12]. For instance, PML nuclear bodies are dynamic
structures, which differ in position, size, number, motional state and
composition as a function of conditions [12,35–37].
Although the physiological impact of PML expression is reasonably
well described, the molecular and biochemical basis for the physio-
logical activities associated with the PML protein and PML nuclear
bodies is poorly deﬁned. Ultimately, one would like to determine PML
nuclear body function at the same level that one understands how
other cellular organelles work. With such an understanding one can
begin to infer how these structures impact on cell physiology and how
their dysregulation contributes to cancer and neurodegeneration.
When considering PML nuclear body function, a few facts should be
kept in mind. These will be discussed in greater detail throughout this
review. The ﬁrst issue is the lack of a signiﬁcant phenotype in PML−/−
mice [12]. These mice apparently develop normally and have only
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the PML gene is not evolutionarily conserved in eukaryotes, being
absent from Drosophila melanogaster, Saccharomyces cerevisiae and
Arabidopsis thalianawhere the sequencing of these genomes has been
completed [12]. In contrast to the PML protein, some PML body cons-
tituents are highly conserved being found in at least a subset of these
organisms. Finally, the PML proteinwas thought to be required for the
organization of PML nuclear bodies i.e. for the organization of any of
the components into spherical nuclear structures. However, this is not
the case for at least endogenous eIF4E [17,39,40] and when human
Sp100 is overexpressed in murine PML knock-out cells (Staege and
Will, in preparation). These ﬁndings with eIF4E suggest that other
evolutionarily conserved proteins could form prototypic nuclear
bodies in the absence of the PML protein. In this way, the PML protein
may not be a required element for the formation of the nuclear struc-
tures it is associated with.
2. Scope of this review
Many important issues relevant to determining the biochemical
and molecular basis for PML function were discussed in our previous
reviews [12,14]. In particular, general experimental limitations for
many areas of “PML-ology” were described. There are several areas
that will not be discussed as excellent reviews are available, with
topics including the role of PML in acute promyelocytic leukemia
(APL), in viral infection, the role of sumoylation, as well as other areas
[1–3,8,10,13,34,36,37,41,42].
In this review, general features of the PML protein and PML nuclear
body function will be discussed and a potential framework for
unifying PML’s disparate functions will be outlined. As stated in our
previous reviews [12,14], studies into the function of the PML protein
and PML nuclear body have relied on answering the following
questions: what nuclear structures are the bodies near to, what
other macromolecules co-localize with the nuclear bodies, and what
are the effects of disrupting the nuclear bodies? These strategies have
not changed signiﬁcantly in the last 5 years and so will only be
discussed brieﬂy here. A model that could provide a unifying frame-
work for the disparate biochemical effects associated with PML is
presented. In the PML RNA regulon model, the PML protein modulates
gene expression in a combinatorial and coordinated fashion by inhi-
biting the eIF4E RNA regulon. As one will see, the PML protein may
modulate other regulons as well and its assembly into nuclear bodies
may enhance this activity. This model provides a molecular basis for
the disparate affects of the PML protein on gene expression and its
activities in what seem to be unrelated biochemical pathways. This
model may provide a starting point for understanding the molecular
underpinnings of the effects of the PML protein and its related nuclear
bodies on proliferation and tumour suppression.
3. PML’s place in the nucleus
PML nuclear bodies are spherical structures generally 0.1–1.0 μm
in size which are distributed throughout the nucleus and are
generally excluded from the nucleolus. PML nuclear bodies are
found in the inter-chromatin space [43,44]. There are, on average, 10–
30 bodies per nucleus. These structures are multi-protein complexes.
Electron microscopy (EM) studies suggest that in many cases these
bodies are donut shaped, i.e. that the PML protein is found in an outer
ring, with the centre of the body “hollow”, or negative for the PML
protein (reviewed in [12]). The PML protein is also found in track-like
structures throughout the nucleus in an isoform dependent manner
[45]. All PML isoforms reported thus far have the RING B-box coiled
coil (RBCC or TRIM) motif [46]. Mutation of the RING or B-boxes leads
to disruption of PML nuclear bodies [47,48]. This disruption is coupled
with a loss of the physiological functions associated with the PML
protein [12]. Treatment of permeabilized cells with RNAse or DNAsedoes not alter the morphology of these bodies, suggesting that nucleic
acid is not required for their structural integrity [12]. The integrity of
PML nuclear bodies is also disrupted by the addition of the guanosine
analogue, m7GpppG, and another cap analogue, ribavirin [17,49].
m7GpppG or ribavirin treatment also leads to disruption of Sp100,
another established PML body component, but this treatment does not
disrupt other nuclear organelles indicating their effects are speciﬁc
[17,50]. Both of these small molecules bind a direct protein partner of
PML, eIF4E (see below), leading to a conformational change in eIF4E
that may contribute to the disruption of PML nuclear bodies [17,49].
Both the PML protein and PML nuclear bodies respond to
extracellular stimuli [51,52]. For instance, treatment of cells with γ-
IFN leads to increased expression of the PML protein due to the
presence of a GAS element in the PML promoter and further, PML
nuclear bodies double in number and size [21,51,52]. Treatment of
cells with heavy metals, such as cadmium, leads to a redistribution of
the PML protein from the nucleus to the cytoplasm [21,51,52].
Obviously, these are only a few, of many, examples of how extra-
cellular stimuli can modulate PML nuclear bodies.
The relationship between structural integrity of PML nuclear
bodies and sumoylation of the PML protein has been studied by
several groups (see reviews [13,34,36,42,53,54]). There are PML nuc-
lear bodies in the absence of sumoylation and thus SUMO is not a
nuclear body targeting signal [13,53]. However, nuclear bodies in the
absence of SUMO appear as “primitive bodies” and do not appear to
have the full complement of PML body components associated with
these [13,53]. Additionally, PML harbours a SUMO binding motif [55]
which may play a role in assembly. Further detailed discussion of the
different isoforms of PML and their functionalities have been covered
in recent reports [45,53].
4. What do neighbours tell us about function?
The relative position of PML nuclear bodies to other nuclear
structures could give some insight into the functionalities of these
structures. For instance, there is a correlation between the spatial
position of PML nuclear bodies with Cajal bodies, cleavage bodies and
splicing speckles [43]. Importantly, these structures do not co-localize
with PML nuclear bodies, but rather are adjacent to PML nuclear
bodies i.e. neighbours [43]. For instance, studies in T24 cells indicate
that one of the four Cajal bodies in each cell is adjacent to a PML
nuclear body [43]. Cajal bodies are thought to be involved in assembly
of spliceosomes and the transcriptome [56], cleavage bodies are
involved in mRNA 3′end processing [57] and Sc35 is involved in pre-
mRNA processing [58]. Thus, it is possible that the PML protein could
play a role in some sort of RNA processing events (for more in depth
discussion see [12]).
PML nuclear bodies appear to have a spatial relationship with
some genomic loci. For instance, one PML nuclear body per cell is
found adjacent to a gene-rich major histocompatibility complex
(MHC) locus on chromosome 6 [59,60]. This association was
independent of the transcriptional status of the cell or of progression
through the cell cycle [59]. Thus, PML nuclear bodies can have speciﬁc
genomic associations independent of transcription [59]. Of course, it is
not known whether there is a functional relationship between PML
nuclear bodies and MHC, or other loci located near to PML bodies.
Early reports suggested there was a link [61]. However, loss of PML
nuclear bodies does not affect the expression of the majority of MHC-I
genes involved in antigen presentation despite its localization to this
loci [60,62,63]. Equally well, these spatial associations could mark a
relationship with other nearby, but as-yet-unidentiﬁed, compart-
ments with which PML nuclear bodies interact. Some studies have
suggested that PML nuclear bodies are close to sites of active
transcription. For instance, up to 30% of PML nuclear bodies partially
overlap with a marker of nascent RNA implicating PML bodies in a role
in transcription [64]. Importantly, approximately 30% of Cajal bodies
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in the same study. Thus, PML could function adjacent to active
transcription sites or act in post-transcriptional functions as do
splicing speckles. Importantly, RNA Polymerase II does not immuno-
precipitatewith the PML protein indicating that the protein is unlikely
to act directly in transcription [20,43]. However in general, no detailed
study controlling for the relative crowding in the nuclear space, and
thus what is the likelihood of random association, has been reported
(to our knowledge). Such a study would be extremely informative in
terms of formulating theories for the connection between PML
nuclear bodies and transcription.
If this type of “neighbour” analysis is used to infer the function of
PML nuclear bodies, one must take into account their motional status.
Interestingly, PML nuclear bodies can be rapidly mobile organelles in
some cellular contexts. A subset of PML nuclear bodies move within
the nucleus in an energy dependent fashion [35]. These studies used
the SP100 protein fused to the yellow ﬂuorescent protein (YFP) in
living BHK cells [35]. Sp100 is a well-established component of PML
nuclear bodies. Three populations of nuclear bodies were observed:
25% of nuclear bodies were stationary, 63% showed minor motions
and 12% showed rapid motions [35]. The minor motions, which
describe the majority of PML nuclear bodies, include localized
movements similar to those observed in other nuclear organelles
such as Cajal bodies [35]. PML nuclear bodies in the rapid class were
typically the smaller nuclear bodies, where different PML nuclear
bodies moved at different times in the nucleus. Motions included not
only translational movements but also the coalescence of small bodies
into larger bodies and conversely, the budding off of small bodies from
larger ones [35]. Movement was not sensitive to RNA Polymerase II
activity but was sensitive to depletion of ATP and was myosin
dependent [35]. Surprisingly, these motions were cell type speciﬁc,
occurring readily in BHK cells but not in HeLa cells [35].
Aside from its nuclear distribution, a substantial fraction of the
PML protein is found in the cytoplasm. In fact, some isoforms of PML
lack the C-terminal nuclear localization signal (NLS) [46,65]. PML is
also found in the cytoplasm in certain pathogenic conditions including
hepatocellular carcinomas [11] and in cells infected with certain
viruses such as HIV and LCMV (reviewed in [12]).
Taken together, these ﬁndings strongly suggest that there are
multiple classes of PML nuclear bodies. For instance not all PML
nuclear bodies in a given nucleus have the same preference for their
neighbours, (e.g. some are near to Cajal bodies or the MHC locus), or
are of the same size. Further, they can have different compositions and
motional properties. The PML protein within structures morphologi-
cally similar to PML nuclear bodies can be found in the cytoplasm,
further demonstrating the challenge for investigators trying to deﬁne
molecular functions for the PML protein and its associated super-
molecular assemblies.
It is important to remember that the nucleus is a crowded place,
and living next door to the ﬁre station, does not necessarily make you
a ﬁreman. Thus, interpretation of these nearest neighbour studies
require careful analysis before they can give us genuine insight into
function(s) of the PML protein and PML nuclear bodies.
5. PML is not evolutionary conserved
Given the central role often purported for the function of the PML
protein and PML nuclear bodies, one would assume that the PML
protein is evolutionarily conserved. However, analysis of several
genomes where the sequencing is complete indicates that this is not
the case [12]. Sequence based analogues of the PML protein are not
found in S. cerevisiae, A. thaliana, D. melanogaster or bacteria [12]. One
study suggested that the PML protein was an analogue of the COP1
plant protein [12]. However, more detailed analysis indicates that
COP1 has a different domain structure (with the exception of the
shared RBCC motif) [12] and that there is a human homologue of thisplant protein named hCOP1 [66]. Of course, there could be functional
homologues of the PML protein with no sequence homology in these
species. However, at least at the sequence level, PML expression seems
to be limited to higher eukaryotes [12]. These observations lead to
some basic questions which remain to be answered — do organisms
lacking the PML protein have some sort of allied nuclear structures
and if so, do these have similar functions to PML nuclear bodies in
mammals? Further, it would appear that mammals have evolved an
additional regulator, the PML protein, to regulate the function of an
evolutionarily more conserved nuclear structure.
Interestingly, there are proteins that are associated with PML
nuclear bodies and that are evolutionarily more conserved than the
PML protein. This includes eIF4E which forms bodies in the absence of
the PML protein (see below). Perhaps subsets of these evolutionarily
more conserved proteins form the structural/functional core or are
organizers of PML nuclear bodies.
6. What’s in a name — is the PML protein required for the
formation of PML nuclear bodies?
Traditionally, PML nuclear bodies are deﬁned by the presence of
the PML protein. Several reports claim that the PML protein is the
central organizer of PML nuclear bodies and thus in its absence, there
are no such nuclear structures [38,67]. For instance, in PML−/− cells, the
PML nuclear body components Daxx and p53 are found distributed
diffusely throughout the nucleus [54,67]. These studies suggest that
these proteins thereby lose substantial functionality in the absence of
being organized into bodies. Re-introduction of PML leads to
formation of PML containing structures and to the recruitment of
Daxx and p53 (and others) to these bodies [54,67]. Typically, the
traditional philosophy would suggest that in the absence of the PML
protein, these proteins are not functional (or as functional) as in the
presence of PML.
However, exciting ﬁndings from Staege and Will (unpublished
observations) indicate that in murine PML−/− cells human Sp100 forms
structures that are morphologically indistinguishable from PML
nuclear bodies and in addition is able to recruit human overexpressed
p53 and endogenous murine Daxx protein. Therefore, PML is not the
only protein that can recruit PML nuclear body components into
nuclear structures. Whether such bodies are functionally distinct from
bodies which also contain the PML protein is yet to be determined.
However, these ﬁndings questions one of the basic tenets of “PML-
ology”, that PML is required for the organization of all the components
into these nuclear structures.
In support of these ﬁndings, earlier studies show that in PML−/−
cells, another PML body component eIF4E, is also found in nuclear
body type structures [17,21]. In PML−/− cells, eIF4E seems to be more
active than in controls suggesting that the absence of the PML protein
leads to dysregulation of eIF4E [17,21]. Importantly, this provides an
example of a protein that is, in fact, both in nuclear structures and is
more active in the absence of PML. If PML nuclear body content is
analyzed in terms of evolutionary conservation, one ﬁnds that the
eIF4E protein is more evolutionarily conserved than the PML protein.
This would suggest that some components form some type of “PML”
nuclear bodies in these “older” organisms. In this way, the PML protein
could be a late arrival (in the evolution context) evolved to regulate a
much older set of structures. For instance, eIF4E forms nuclear body
structures in D. melanogaster, where no sequence homologue of the
PML protein is observed [12]. Similarly, eIF4E nuclear bodies are
observed in Xenopus laevis [14], where no sequence homologue of
PML is obvious. However, there appears to be a sequence homologue
of PML in chicken (with 30% homology to human PML), suggesting
that it can be found in other vertebrates (Skrabanek and Borden, un-
published observations). Thus, one might expect that proteins which
are more evolutionarily conserved would form structures in the
absence of the PML protein [12]. In this way, organelle functionmay be
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bodies have related or distinct functions to their PML containing
counterparts in mammalian cells, remains to be determined.
In summary, there are components of nuclear bodies that do not
require the PML protein to form nuclear body type structures. This is
in contrast to one of the basic tenets of the ﬁeld: that the PML protein
is the component required for the formation of these nuclear
structures. Only further studies will elucidate whether evolutionary
conservation will be a good predictor of this body-forming ability. It
may be that identifying the structural underpinnings of PML nuclear
bodies is akin to peeling an onion, the PML protein may be just one
layer in the middle and PML-ologists must continue peeling until
they ﬁnd the centre. Clearly, these ﬁndings unleash a semantics
argument — what should these structures be called in the absence of
the PML protein?
7. Biochemical functions of PML and its associated bodies
Establishing the composition of PML nuclear bodies is an area of
both great interest and substantial technical difﬁculty. To date, over 70
proteins have been reported to localize with PML nuclear bodies
(Nuclear Protein Database http://npd.hgu.mrc.ac.uk). Identiﬁcation of
proteins which bind the PML protein is used as a means to assign
function to the PML nuclear body itself [12]. This is mainly due to the
fact that the PML protein does not have many deﬁned biochemical
activities associated with it. Two direct and distinct biochemical
activities have been reported to date: 1. SUMOmodiﬁcationwhere the
RING domain of PML interacts with the SUMO E2, Ubc9, acting in auto-
sumoylation [68–71], and 2. reduction of the afﬁnity of eIF4E for its
ligand, the m7GpppG cap, by about 100 fold [17,71]. This latter activity
will be discussed at length below. Potentially, direct interactions
might give one unique insight into the function of the PML protein,
and thus the body. To date, there are only a few components of PML
nuclear bodies that are known to directly interact with the PML
protein, for example: eIF4E, SUMO/PIC1, Ubc9, PRH/Hex (the proline
rich homeoprotein) and the viral protein Z [68,69]. Importantly, PML
contains a SUMO bindingmotif [55], and thus could potentially recruit
other SUMO modiﬁed proteins to the body, this possibility would be
an interesting future direction of investigation. There have been other
proteins suggested to directly bind the PML protein, but these assays
are typically done in reticulocyte lysates, rather than using two
puriﬁed proteins. Thus, they are not established direct targets. How-
ever, subsequent experiments with puriﬁed proteins may demon-
strate they are also direct partners.
Many groups have attempted to purify PML nuclear bodies. The
tight association of PML nuclear bodies with the nuclear “matrix” and
the fact that the PML protein is found both in the nucleoplasm as well
as in nuclear bodies have presented confounding issues in the
puriﬁcation of intact nuclear bodies and thus, in the determination
of their composition. Further, PML nuclear bodies are heterogeneous
in nature, thus not all PML nuclear bodies are likely to be equivalent in
terms of structure, composition, function, spatial distribution and
motional properties. This heterogeneity even occurs in the same cell.
Clearly, it seems likely that not all components will be present at all
PML nuclear bodies all of the time. Further, not all PML nuclear bodies
may be structurally or functionally equivalent.
8. The physicality of PML nuclear bodies?
The wide variety of partner proteins, and the compositional
heterogeneity of PML nuclear bodies, even in the same nucleus, has
led to the suggestion that PML nuclear bodies are some sort of nuclear
storage facility [8,34]. Consistent with this model, many foreign and
inappropriately expressed proteins are found accumulated at PML
nuclear bodies. For instance, when transfected into cells, the lac
repressor localizes to PML nuclear bodies [72]. In addition, severalproteins involved in polyglutamine repeat diseases such as huntingtin,
ataxin 1 and ataxin 3 (in their expanded forms) localize to these
bodies [4,5,35,73]. In these neurological disorders, PML nuclear bodies
appear to be much larger than normal nuclear bodies and more
inclusion-like [4,5,73]. PML nuclear bodies are sometimes adjacent
to proteosomal components [53]. Their presence adjacent to PML
nuclear bodies is consistent with this role as a sensor of foreign/
inappropriately expressed proteins and also with many other po-
tential functions of PML nuclear bodies. Additionally, it has been
proposed that PML nuclear bodies store normal, functional proteins.
In this way, the body could serve to titrate levels of the active forms
of these proteins in the nucleoplasm and thus modulate bioche-
mistries there [8]. This is consistent with the proposition that
other types of nuclear bodies are storage areas for certain types of
components.
It has also been hypothesized that PML nuclear bodies could form
catalytic surfaces with speciﬁc biochemistries occurring on the surface
of the body [74,75]. RING domains from several proteins, including
the PML protein, self assemble into spherical structures visible by EM
[74]. PML and the viral protein Z self assemble into structures and
are better inhibitors of eIF4E in their assembled state than in their
monomeric state [74]. Mdm2 and BRCA1/BARD1 act similarly, where
they assemble into spherical structures with their corresponding E2
proteins assembling on to the spheres [74,76]. Again, the assembled
Mdm2 and BRCA1/BARD1 forms are better E3 ligases than their cor-
responding monomeric forms [74,76].
Whether or not PML nuclear bodies are nuclear storage facilities or
catalytic surfaces (or both) remains an open question. Both of these
would provide a molecular basis for the speciﬁc biochemistries
associated with PML nuclear bodies.
9. The PML protein and PML nuclear bodies — all things to
all men?
The PML protein and consequently, PML nuclear bodies, have been
attributed functions in diverse, and apparently unrelated biochemical
activities such as DNA repair, DNA replication, transcription, mRNA
export, and sites of post-translational modiﬁcation (reviewed in
[12,34]). The data supporting these models has been described else-
where in detail, and thus will not be discussed here (e.g. in [12,34]).
Generally, these functions are attributed to PML nuclear bodies based
on its proximity to, or interactions with, proteins or structures of
known function, as discussed above. Such disparate activities could
arise from a number of factors (which are not mutually exclusive). For
instance, PML nuclear bodies could be so heterogeneous that bodies
in different cell types, under different physiological conditions, or
variance of bodies within the same nucleus, mean that they simply
function in different biochemistries. Alternatively, it could be that
the PML protein and thus PML nuclear bodies function in some pro-
cess(es) so basic, that it impacts on all of these biochemical pathways.
We propose that these structures impact coordinately and combina-
torially on gene expression by inhibiting a key node in an RNA regulon
governing cell proliferation and survival [15,19,77]. This PML RNA
regulon model provides a theoretical basis to understand many PML
associated phenomenon. The model is described below.
10. RNA regulons — a unifying framework for PML nuclear body
function?
The PML protein and PML nuclear bodies were shown to interact
with eIF4E by several groups [20,71,78–80]. eIF4E functions in cap
dependent translation in the cytoplasm [17] and mRNA export of
speciﬁc transcripts in the nucleus [77]. In fact, eIF4E is a central node
in an RNA regulonwhich governs proliferation and survival [15,19,77].
Our studies show that the PML protein is a potent inhibitor of this
regulon [15,19,77].
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colleagues as a means to explain how post-transcriptional regulation
could be coordinated in eukaryotes [81–83]. This parallels the operon
model in prokaryotes. Here, all the genes for the same biochemical
pathway, such as tryptophan biogenesis, are adjacent to each other
and are co-regulated by the same promoter. Further, transcription and
translation occur at the same time on the transcript. In this way, pro-
karyotes can readily coordinate production of all of the proteins
necessary for a given biochemical pathway. The situation in eukar-
yotes is vastly different. Genes coding for proteins in the same
biochemical pathway do not appear to be spatially organized, in
general. Further, once the genes are transcribed, even if transcription
is coordinated by the use of commonpromoter elements, the resulting
mRNAs may not have, for instance, similar stabilities, nuclear export
rates or translation efﬁciencies. The RNA regulon model proposed that
RNAs in a given pathway are co-regulated by the presence of distinct
sequences in their UTRs referred to as USER codes. These codes enable
them to be regulated at particular levels of gene expression e.g. mRNA
export, translation, stability etc. The combination of USER codes in the
RNA would ultimately determine its fate. RNAs with the same com-
bination of USER codes would be coordinately regulated permitting
the production of, for instance, all the proteins in some metabolic
pathway such as tryptophan biosynthesis.
Our studies suggest that the PML protein is a potent inhibitor of
eIF4E, which is a key node in an RNA regulon governing proliferation
and survival [18,19,77]. eIF4E promotes proliferation and rescues cells
from apoptosis. Although eIF4E acts in the cap dependent translation
of all mRNAs, its overexpression only leads to enhanced translational
efﬁciency of a subset of transcripts usually referred to as eIF4E sen-
sitive mRNAs [84]. Translational efﬁciency refers to the observation
that these transcripts are loaded onto heavier polysomes (which are
more efﬁcient) without changing the amount of mRNA present [84]. InFig. 1. The PML regulon model is used to explain the effects of the PML protein and PML nuclea
an explanation for the transcriptional independence of PML promoted apoptosis [86]. Recent d
[15]. eIF4E can promote Akt activation in a NBS1 dependent manner [15]. Furthermore, eIF4E p
downstream effectors of Akt as shown. Proteins in blue have their levels upregulated at the mR
these proteins by impairing eIF4E dependent mRNA export of their corresponding mRNAs [1
through inhibiting eIF4E activity [15]. Thus PML overexpression impairs Akt signaling at (at leas
Akt and conversely, red indicate that it is inhibited. For clarity of presentation, the completeaddition, the nuclear fraction of eIF4E acts in mRNA export providing
more mRNA for translation and thus, increased production of these
proteins without necessarily having these transcripts loaded pre-
ferentially onto heavier polysomes [77]. In particular, it promotes the
nuclear export of mRNAs involved in proliferation and survival via the
presence of a ~50 nucleotide sequence found in the UTR of these RNAs
[19]. This sequence is referred to as the eIF4E sensitivity element
(4E-SE) [19]. RNAs can be sensitive to eIF4E at the export level (e.g.
cyclin D1), translation efﬁciency level (e.g. VEGF) or both (e.g. ODC and
Pim1) [19,77]. Our studies show that the PML protein directly binds
eIF4E and thereby inhibits nuclear export of these mRNAs [71,77]. The
PML protein achieves this by reducing the afﬁnity of eIF4E for the m7G
cap moiety on these RNAs by about 100 fold [17,71].
The ability of the PML protein, and presumably PML nuclear
bodies, to inhibit a network node in an RNA regulon potentially pro-
vides an explanation for several of the physiological and biochemical
phenomenon associated with the PML protein (Figs. 1 and 2). For
instance, several groups have shown that PML overexpression pro-
motes apoptosis in a variety of contexts [85–87]. Similarly, eIF4E is
known to rescue cells from apoptosis in several contexts e.g. [88,89].
Our studies demonstrate that PML overexpression dramatically
inhibits eIF4E mediated apoptotic rescue during serum deprivation
in ﬁbroblasts (the only context examined thus far) [15]. We propose
that the PML protein does this by inhibiting the eIF4E regulon [77].
The positioning of eIF4E in a survival network including Akt is
central to its survival function [15] (summarized in Fig. 1). Recent
studies indicate that eIF4E activates the Akt pathway at two levels
[15]. First, overexpression of eIF4E leads to increased phosphorylation
of Akt via increased expression of NBS1, a protein involved in activ-
ation of Akt through an interaction with PI3K [90,91]. Here, eIF4E
overexpression leads to enhanced NBS1 mRNA export, and thus
elevated protein levels, of NBS1. eIF4E overexpression is correlatedr bodies on survival signaling as described in the text. This is the ﬁrst model that provides
ata indicate that eIF4E is a node in a regulon governing cellular proliferation and survival
romotes the mRNA export (and in some cases also the translational efﬁciency) of several
NA export level by eIF4E [18]. Conversely, PML overexpression inhibits the production of
8]. Further, PML overexpression impairs Akt activation by inhibiting production of NBS1
t) two levels [15]. Green arrows indicate that the activity of the given factor is enhanced by
Akt pathway and other possible feedback loops are not depicted.
Fig. 2. The PML regulonmodel is used to explain the effects of the PML protein on p53 signaling. As described in the text, PML overexpression leads to reduced eIF4E activity which in
turn leads to reduced Mdm2 mRNA export. Note that eIF4E promotes Mdm2 protein production at the level of mRNA export, not at the level of translation [19,101,120]. In this way,
overexpression of PML leads to enhanced p53 levels which in turn lead to enhanced PML levels given observations that PML is a downstream effector of p53 [98]. For clarity of
presentation, all the interactions described in the text (and others reported in the literature) are not depicted.
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These activities of eIF4E are PI3K and NBS1 dependent [15]. Im-
portantly, eIF4E cannot rescue Akt1−/− cells from serum deprivation
induced apoptosis, thus its activity is Akt1 dependent in this context.
The second level by which eIF4E activates Akt signaling is by inc-
reasing the expression of downstream effectors of Akt such as cyclin
D1 and c-myc [19,92] (see Fig. 1). Thus eIF4E can impact on Akt sig-
naling both upstream of Akt through NBS1 and by increasing the
concentrations of downstream effectors of Akt.
The PML protein is a potent inhibitor of these eIF4E-mediated
effects [17–19,71,77]. For instance, PML overexpression leads to
inhibition of Akt phosphorylation, at least in part, via reduction in
mRNA export of NBS1, thus leading to reduced levels of this upstream
Akt activator [15,91]. PML nuclear bodies also interact with NBS1 [93],
thus it may have yet another level of control on the eIF4E regulon [77].
This may also segue into understanding the link between PML nuclear
bodies, NBS1 and DNA repair. Further, PML overexpression leads to
reduction in the levels of downstream effectors of Akt such as cyclin
D1 and c-myc [18–20,92]. Again, this is due, at least in part, to reduced
mRNA export and thus expression, of these genes. Thus, the PML
protein potently impedes the apoptotic rescue function of eIF4E, at
least in part, through these activities [15]. These ﬁndings are con-
sistent with observations that PML overexpression leads to decreased
phosphorylation of Akt [15,94]. Further, it is consistent with the
observation by another group that PML−/− cells have increased levels of
activated Akt [94]. Clearly, different apoptotic stimuli will utilize
different genetic pathways. In summary, the role for the PML protein
and PML nuclear bodies as inhibitors of an RNA regulon provides a
theoretical context in which to understand the mechanism by which
PML overexpression promotes apoptosis during serum deprivation of
ﬁbroblasts. In support of our model, the PML protein requires its RING
domain to promote apoptosis, to bind eIF4E, to impair eIF4E activityand to form nuclear bodies [17,71,85]. Further, these data provide an
explanation for the previous observation that PML overexpression
promotes apoptosis independent of ongoing transcription [86].
Another (not mutually exclusive) explanation has been proposed
to understand the effects of the PML protein on mTOR and Akt
activation [16,94]. One study suggests that mTOR and Akt may co-
localize with PML nuclear bodies [94]. In this study, the authors
suggest that the PML protein inactivates Akt by recruiting phospha-
tase PP2a into PML nuclear bodies. Importantly, this model would
require novel modes for mTOR and Akt function, since these proteins
are usually associated with the plasma membrane.
The RNA regulon also provides a theoretical context in which to
understand the relationship between PML, Mdm2 and p53 protein
levels (Fig. 2). Several models have been described to explain the
following observations. In some conditions, PML and p53 co-localize
at PML nuclear bodies [24]. Other studies suggested that PML nuclear
bodies could modulate the acetylation of p53 by recruiting CBP, an
acetyltransferase, as well as p53, to the bodies [32]. PML nuclear
bodies may also act in the recruitment of Chk2 and HIPK2 kinases to
facilitate phosphorylation and activation of p53 under stress condi-
tions [95–97]. PML itself is a target gene of p53 and may be a key
downstream effector of p53 activity [98]. In PML−/− cells, there is less
p53 protein than in controls both under steady state conditions and
during γ-irradiation [99,100]. Introduction of PML into PML−/− cells
leads to increased levels of p53 [99,100]. These changes in gene
expression are paralleled by expected changes in cell physiology.
The role of the PML protein as an inhibitor of the eIF4E RNA
regulon provides a basis for understanding the relationship between
PML and p53 expression. Previous studies showed that eIF4E en-
hances the expression of Mdm2, a negative regulator of p53 [19,101].
eIF4E enhances the mRNA export, but not the translational efﬁciency,
of Mdm2 mRNA [19,101]. PML inhibits eIF4E dependent mRNA export
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tently, PML overexpression leads to elevated levels of p53 [99].
Interestingly, p53 overexpression leads to transcriptional repression of
eIF4E and thus, decreased eIF4E protein levels [102]. Mdm2 over-
expression leads to reduced p53 and increased eIF4E levels [102]. This
could constitute a feedback loop, whereby increased eIF4E levels cor-
relate with enhanced Mdm2 mRNA export. The interaction between
PML and Mdm2 proteins provides more intricate feedback loops
[99,103,104]. Co-expression of Mdm2 and PML leads to the redis-
tribution of PML to the cytoplasm leading to destabilization of p53
[105]. Further, increased p53 levels result in reduced translation ini-
tiation via dephosphorylation of 4EBP-1, which consequently causes
formation of translationally impaired eIF4E complexes [106]. Thus, the
role of the PML protein as an inhibitor of the RNA regulon provides a
theoretical basis to understand its effects on p53 activity.
The growth and transformation suppressive activities of the PML
protein and PML nuclear bodies can also be understood in the regulon
context. PML overexpression leads to a G1/S arrest in several cell types
(reviewed in [12]). PML overexpression leads to reduction in several
proteins involved in cell cycle progression including: cyclin D1, cyclin
B1, cyclin E1, c-myc and cyclin A2 (to name a few) [19,20,107,108].
Consistently, loss of PML expression alters c-myc target gene ex-
pression [109]. All of these mRNAs are eIF4E mRNA export targets and
their mRNA export is inhibited by PML [18,19]. The PML protein
requires its RING domain for both its growth suppressive activities and
its ability to impair production of these proteins [12,17,19]. Interest-
ingly, cyclin D1 mRNA export and cyclin D1 protein levels are elevated
in PML−/− cells relative to controls [18,21]. γ-IFN does not reduce cyclin
D1 mRNA export or protein levels in PML−/− cells, but does so in
wildtype cells, where PML protein levels are elevated due to γ-IFN
dependent transcription of PML [21]. Re-introduction of PML into
PML−/− cells leads to reduced cyclin D1 mRNA export and protein
levels [21]. In this way, the PML protein can coordinately impact on
cellular proliferation in response to extracellular stimuli.
PML suppresses eIF4E mediated oncogenic transformation [17].
The mRNA export function of cyclin D1 contributes to the oncogenic
potential of eIF4E [18]. The presence of the 4E-SE USER code in cyclin
D1 mRNA substantially promotes the ability of eIF4E to transform
cyclin D1−/− cells when cyclin D1 constructs are re-introduced [18].
Clearly, as an inhibitor of eIF4E dependent mRNA export, PML’s trans-
formation suppressive activities (in this context) can be understood
using the RNA regulon model.
Several studies suggest that PML activity may be lost as part of the
metastatic process through reduced levels of the PML protein or
relocalization of the PML protein to the cytoplasm [11,45,110,111].
Tumour angiogenesis may be increased in a prostate cancer model
using PML−/− mice [16]. It was suggested that the PML protein reduces
HIF1α protein synthesis without modulating HIF1α RNA levels [16].
This reduction in HIF1α correlates with reduced VEGF levels. Note that
increased VEGF levels correlate with increased metastasis [112,113].
How can the PML protein impact on protein synthesis, a cytoplasmic
event? The PML protein could impact on mTOR and thereby reduce
HIF1α, although deletion of the 5′UTR of HIF1α did not modulate its
synthesis in the presence or absence of the PML protein [16]. This is
somewhat surprising given that translational control is usually
through this region, as discussed by the authors. The authors suggest
the possibility that the PML protein impacts on translation of HIF1α
through sequestering mTOR in PML nuclear bodies during hypoxia
[16]. Additionally, it is possible that the PML protein could impact on
the mRNA export of HIF1α (this has yet to be examined). Further, the
PML protein inhibits Akt phosphorylation (which thereby impacts on
mTOR activation) via its effects on the RNA regulon [15]. The PML
protein could also impact on metastasis by reducing the production of
ODC, another protein important for this process, given that ODC
mRNA export is impeded by PML [19]. Thus, the PML protein could
also reduce VEGF levels independently of HIF1α, via its effects oneIF4E and Akt. Further, PML could affect metastasis via its effects on
other gene products such as ODC.
In summary, the PML protein is positioned to coordinately and
combinatorially modulate gene expression through its inhibitory
effects on eIF4E, a network node in an RNA regulon. This model for
function of the PML protein and PML nuclear bodies provides a circuit
diagram level of understanding for PML associated phenomenon.
Clearly, PML is likely to have eIF4E independent functions, and these
may be by acting on other RNA regulons. For the regulon model
described here, the question is an obvious one: why don’t PML−/−mice
have aggressive cancers? The answer appears to be redundancy in the
regulation of eIF4E. For instance, in PML−/− cells, eIF4E associates with
other negative regulators including the proline rich homeodomain
protein PRH/Hex [70,114,115]. This is addressed below.
11. Why are the PML−/− mice well?
One of the nagging issues in “PML-ology” is the lack of a more
striking phenotype in the PML−/− mice [38,116,117]. The PML−/− mice
appear morphologically normal, where loss of the gene does not
impact on survival [38]. PML−/− mice are ~2 fold more resistant to γ-
irradiation than normal mice [38,117]. PML−/−mice treatedwith DMBA
and tetradecanoyl phorbol acetate developed about twice as many
papillomas than controls and these mice have a ~2 fold reduction in
TNFα response [38,87]. However, many reports describe a wide
variety of activities that absolutely require the PML protein. Thus, one
is faced with a choice: either that activity is not critical for the health
of the cell/animal, or that the PML protein is one of many redundant
regulators that can modulate a given process. Additionally, these
factors may suffer from a loss of efﬁciency when not organized into
nuclear bodies (as discussed for the catalytic surface hypothesis sec-
tion above). In this case, the factors may functionwell enough formost
situations and only in stress situations is the reduced efﬁciency phen-
type more obvious.
It is clear that redundancy plays a major role with regard to the
activities of the PML protein and PML nuclear bodies in the eIF4E RNA
regulon. Over 200 homeoproteins are positioned to modulate eIF4E
dependent changes in gene expression [70,118]. These homeoproteins
bind the same region of eIF4E that is recognized by the PML protein
[70,114,118]. These homeoproteins can either stimulate or repress
eIF4E dependent gene expression [70,118]. These homeoprotein regu-
lators of eIF4E are phylogenetically more conserved than the PML
protein, allowing modulation of the eIF4E regulon in a wide variety of
evolutionary contexts. A speciﬁc example of a redundant regulator is
found in the proline rich homeodomain PRH, which negatively
regulates eIF4E in APL cells [70] (where the PML protein is displaced
from nuclear bodies) [70]. In APL cells prior to ATRA treatment, PRH
and eIF4E form nuclear structures indistinguishable from PML nuclear
bodies despite themicro-particulate distribution of the PML protein in
these cells [70]. Consistently, APL cells do not have dysregulated eIF4E
activity [17], but of course, they do have a variety of other unrelated
problems that contribute to their oncogenic nature. It is likely that
redundancy in control of the regulon is not complete and thus under
certain conditions, the redundant factorsmay not be as effective as the
PML protein.
12. Insights from the PML regulon model into drug design
Given the medical relevance of PML, interest in the PML protein
and PML nuclear bodies goes well beyond understanding basic
questions in cell biology. It is clear that understanding the function
of these entities could aid in the design and development of novel
therapeutic strategies. The proposed PML regulon model appears to
explain many of the observations regarding the effects of PML on
certain pathways and its physiological effects. A disadvantage of this
model is that it does not describe a physical picture of how PML
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model is that it has allowed speciﬁc insights into how one might
predict other physiological effects of the PML protein and PML nuclear
bodies. Further, it provides a model for drug design because it strongly
suggests that ﬁnding a means to inhibit eIF4E (as the PML protein
does), will enable one to shutdown its associated proliferation/trans-
formation/survival activities at a network level. In this case, the PML
protein inhibits eIF4E by reducing its afﬁnity for the m7G cap.We used
a parallel strategy to the PML protein, whereby we found a small
moleculemimic of them7G cap, ribavirin, which inhibits eIF4E and the
regulon similarly to the PML protein ([50,77,119] and Tan et al.,
submitted for publication). Thus the precise mechanisms bywhich the
PML protein and ribavirin inhibit eIF4E are different, but the overall
strategy of interfering with m7G cap binding is the same. Importantly,
ribavirin inhibits eIF4E mediated transformation and apoptotic rescue
by targeting the eIF4E regulon (Tan et al., submitted for publication).
This has led to a phase II clinical trial in acute myeloid leukemias with
dysregulated eIF4E (www.ribatrial.com; [50,77,119]). This phase II
trial, the ﬁrst to look at the efﬁcacy of inhibiting eIF4E and the regulon
(that we are aware of), started enrolling patients in 2007 and shows
promising results with regard to this strategy (our unpublished
observations).
13. The missing pieces of the puzzle
Clearly there are limitations to this, as with any, model. For
instance, this model only describes PML protein and nuclear body
function at the level of a circuit diagram. This is useful in generally
understanding why PML affects certain pathways and has particular
biological effects. This is the ﬁrst model proposed that could provide a
framework to understand why the PML protein and PML nuclear
bodies can act in so many different pathways. It also could be useful in
predicting new pathways and functionalities for both the PML protein
and its associated nuclear bodies. However, generally, one cannot
build a transistor with only a circuit diagram. In this way, the regulon
model does not address the issue of the “nuts and bolts” of how PML
nuclear bodies function, how they are structured/organized, or how
nuclear body heterogeneity impacts on PML function (to name a few).
Equally well, there are likely functions of the PML protein and PML
nuclear bodies which are independent of eIF4E, and in this way, the
PML regulon may, in part, reﬂect the heterogeneity of this system. It is
interesting to note that some PML partner proteins, such as c-myc,
Mdm2 and NBS1 [93,104,109], are also regulated by the PML protein at
the RNA regulon level, suggesting that there could be some sort of
intricate feedback loop on this PML circuit.
How do we move forward to ﬁnd the missing pieces of the PML
puzzle? Can we ﬁt the pieces we have together? To date, composition
alone has not provided a unifying framework to understand the diverse
phenomenon associated with PML nuclear bodies. The development of
new strategies to micro-dissect composition and thus account for body
heterogeneity would give clearer insight into PML nuclear body func-
tions. Additionally, high-resolution ultra-structure analysis would be
extremely useful. In summary, the PML ﬁeld continues to struggle with
the identiﬁcation of a unifying function for these bodies.We present the
PML RNA regulonmodel, whichmay serve to provide an understanding
of PML associated phenomenon at the circuit diagram level. To our
knowledge, such a model would be the ﬁrst step in describing a
unifying framework for PML function. However, the one constant in
“PML-ology” remains, there are more questions than answers.
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